Restricted accessResearch articleFirst published online 2018-10
Association of Preprocedural Hyperglycemia With Contrast-Induced Acute Kidney Injury and Poor Outcomes After Emergency Percutaneous Coronary Intervention
We investigated whether preprocedural hyperglycemia was associated with contrast-induced acute kidney injury (CI-AKI) and long-term outcomes in patients with acute coronary syndrome (ACS) who underwent emergency percutaneous coronary intervention (PCI). Patients (n = 558) with ACS who underwent emergency PCI were consecutively enrolled. Preprocedural hyperglycemia was defined as glucose levels >198 mg/dL (11 mmol/L). The primary outcome was CI-AKI (≥0.3 mg/dL absolute or ≥50% relative serum creatinine increase 48 hours after contrast medium exposure). Overall, 103 (18.5%) patients had preprocedural hyperglycemia and 89 (15.9%) patients developed CI-AKI. The incidence of CI-AKI was significantly higher in patients with hyperglycemia than without (28.2% vs 13.2%; P < .01). Multivariate analysis indicated that preprocedural hyperglycemia was an independent predictor of CI-AKI (odds ratio = 1.971, 95% confidence interval [CI]: 1.129-3.441; P < .05). In addition, preprocedural hyperglycemia was associated with an increased risk of all-cause mortality during the 2-year follow-up (hazard ratio = 2.440, 95% CI: 1.394-4.273; P = .002). Preprocedural hyperglycemia is a significant and independent predictor of CI-AKI and long-term outcomes.
MarenziGLauriGAssanelliE. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780–85.
2.
IvanesFIsorniMAHalimiJM. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty. Arch Cardiovasc Dis. 2014;107(8-9):424–32.
3.
LiuYLinLLiY. Relationship between the urine flow rate and risk of contrast-induced nephropathy after emergent percutaneous coronary intervention. Medicine (Abingdon). 2015;94(50):e2258.
4.
OzturkDCelikOErturkM. Utility of the logistic clinical syntax score in the prediction of contrast-induced nephropathy after primary percutaneous coronary intervention. Can J Cardiol. 2016;32(2):240–46.
5.
SubramanianSTumlinJBapatBZyczynskiT. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10(2):119–34.
6.
SeeligerESendeskiMRihalCSPerssonPB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007.
7.
WatabeHSatoAHoshiT. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J Cardiol. 2014;174(1):57–63.
8.
OmarASSalamaAAllamM. Association of time in blood glucose range with outcomes following cardiac surgery. BMC Anesthesiol. 2015;15:14.
9.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–99.
10.
AlpertMACarlinoC. Pre-procedural blood glucose levels: a new risk marker for contrast-induced acute kidney injury in patients without diabetes with acute myocardial infarction. J Am Coll Cardiol. 2010;55(14):1441–43.
11.
MarenziGMetrioMDRubinoM. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. Am Heart J. 2010;160(6):1170.
12.
NaruseHIshiiJHashimotoT. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing emergency coronary intervention. Circ J. 2012;76(8):1848–55.
13.
NakamuraTAkoJKadowakiT. Impact of acute hyperglycemia during primary stent implantation in patients with ST-elevation myocardial infarction. J Cardiol. 2009;53(2):272–77.
14.
StegPGJamesSKAtarD. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619.
15.
MehtaRLKellumJAShahSV. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
16.
MorcosSKThomsenHSWebbJA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). EurRadiol.1999;9(8):1602–13.
17.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–266.
18.
MaioliMTosoALeonciniMMichelettiCBellandiF. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv. 2011;4(5):456–62.
19.
LinKYZhengWPBeiWJ. A novel risk score model for prediction of contrast-induced nephropathy after emergent percutaneous coronary intervention. Int J Cardiol. 2017;230:402–412.
20.
MarenziGMetrioMDBartorelliAL. Author’s reply to acute hyperglycemia: is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function. Am Heart J. 2011;162(1):e7.
21.
TurcotDBKiernanFJMckayRGGreyNJBodenWPerdrizetGA. Acute hyperglycemia: implications for contrast-induced nephropathy during cardiac catheterization. Diabetes Care. 2004;27(2):620.
22.
StolkerJMMcculloughPARaoS. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol. 2010;55(14):1433–1440.
23.
MoriyamaNIshiharaMNoguchiT. Admission hyperglycemia is an independent predictor of acute kidney injury in patients with acute myocardial infarction. Circulation J. 2014;78(6):1475–1480.
24.
ShachamYGalozALeshemrubinowE. Admission glucose levels and the risk of acute kidney injury in nondiabetic ST segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Cardiorenal Med. 2015;5(3):191–198.
25.
KnopfWDChronosNChenJP. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol. 2009;103(12):1657–1662.
26.
NishioKShigemitsuMKusuyamaT. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med. 2006;7(2):54–60.
27.
WeizmanREldarMHodH. Effects of uncomplicated acute myocardial infarction on biochemical parameters of stress and sexual function. Psychosomatics. 1991;32(3):275–79.
28.
ArbelYShmueliHHalkinA. Hyperglycemia in patients referred for cardiac catheterization is associated with preexisting diabetes rather than a stress-related phenomenon: a prospective cross-sectional study. Clin Cardiol. 2014;37(8):479–84.
29.
CatherwoodMAPowellLAAndersonPMcmasterDSharpePCTrimbleER. Glucose-induced oxidative stress in mesangial cells. Kidney Int. 2002;61(2):599–608.
30.
O’DonnellDHMoloneyMABouchier-HayesDJLeeMJ. Contrast-induced nephrotoxicity: possible synergistic effect of stress hyperglycemia. AJR Am J Roentgenol. 2010;195(1):45–9.
31.
ShachamYLeshem-RubinowESteinvilAKerenGRothAArbelY. High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention. Clin Exp Nephrol. 2015;19(5):838.
32.
TrachtmanHFutterweitSCrimminsDL. High glucose inhibits nitric oxide production in cultured rat mesangial cells. J Am Soc Nephrol. 1997;8(8):1276–1282.
33.
WasakiMSugimotoJShirotaK. Glucose alters the susceptibility of mesangial cells to contrast media. Invest Radiol. 2001;36(7):355–62.
34.
WilliamsSBGoldfineABTimimiFK. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97(17):1695–701.
35.
HorowitzJDChongCRNgoDTSverdlovAL. Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down. J Thorac Dis. 2015;7(12):E607.
36.
MelinJHellbergOFellströmB. Hyperglycaemia and renal ischaemia-reperfusion injury. Nephrol Dial Transplant. 2003;18(3):460–462.
37.
CapesSEHuntDMalmbergKGersteinHC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773.
38.
IshiharaMInoueIKawagoeT. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J. 2003;146(4):674–78.
39.
ChenPCChuaSKHungHF. Admission hyperglycemia predicts poorer short- and long-term outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Diabetes Investig. 2014;5(1):80.
40.
SongHFLiHWZhaoSMWangSLiXH. The predictive value of admission hyperglycemia in hospital and long-term mortality of diabetics versus non-diabetics with acute coronary syndrome. Zhonghua Nei Ke Za Zhi. 2013;52(7):570–3.
41.
ZhaoSMurugiahKLiN. Admission glucose and in-hospital mortality after acute myocardial infarction in patients with or without diabetes: a cross-sectional study. Chin Med J (Engl). 2017;130(7):767–75.
42.
KosiborodMInzucchiSEKrumholzHM. Glucometrics in patients hospitalized with acute myocardial infarction defining the optimal outcomes-based measure of risk. Circulation. 2008;117(8):1018–27.
43.
ObrebskaAKowalskiJ. The prognostic value of hyperglycemia, leukocytosis and decreased glomerular filtration rate in acute coronary syndromes—pharmacological protection capabilities. Pol Merkur Lekarski. 2014;37(220):240–3.
44.
IngelsCDebaveyeYMilantsI. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J. 2006;27(22):2716–2724.
45.
KrinsleyJS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79(8):992–1000.
46.
Van den BergheGWoutersPJBouillonR. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31(2):359–366.
47.
ArabiYMDabbaghOCTamimHM. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med. 2008;36(12):3190.
48.
GandhiGYNuttallGAAbelMD. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med. 2007;146(4):233–43.
49.
RosaGDCDLDonadoJHRestrepoAH. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care. 2008;12(5):R120.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
